JAK2 and ankylosing spondylitis: In our cases series, a patient treated with JAK2 inhibitor, indeed, developed MZL; however, it should be noted that this patient's exposure to anti-TNF (tumor necrosis factor) agents for her ankylosing spondylitis could have also contributed to her lymphoma [19].